La vendita allo scoperto per CryoPort dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di CryoPort. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

CryoPort (NASDAQ:CYRX) Azioni, Report sulle vendite allo scoperto

CryoPort

CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.

CryoPort Inc

Roth MKM analyst Richard Baldry maintains CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) with a Buy and lowers the price target from $18 to $15.

News

Price Target

Analyst Ratings

CYRX

Roth MKM Maintains Buy on CryoPort, Lowers Price Target to $15

CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) affirms FY2024 sales outlook from $225.00 million-235.00 million to $225.00 million-235.00 million.

Guidance

CryoPort Affirms FY2024 Sales Guidance to $225.00M-235.00M  VS Est.229.73M

CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.31) by 93.55 percent. The company reported quarterly sales of $56.664 million which missed the analyst consensus estimate of $58.042 million by 2.37 percent. This is a 0.90 percent increase over sales of $56.157 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

CryoPort Q3 2024 GAAP EPS $(0.02) Beats $(0.31) Estimate, Sales $56.664M Miss $58.042M Estimate

Partnership Coincides with the Grand Opening of Cryoport's State-Of-The-Art IntegriCell&#x2122;&nbsp;Houston Facility
NASHVILLE, Tenn. and HOUSTON, Oct. 22, 2024 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4283560-1&amp;h=1582915588&amp;u=https%3A%2F%2Fcryoportinc.com%2F&amp;a=Cryoport%2C+Inc.">Cryoport, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) ("Cryoport"), a global leader in supply chain solutions for the life sciences industry, and <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4283560-1&amp;h=2818938700&amp;u=https%3A%2F%2Fwww.giveblood.org%2F&amp;a=Gulf+Coast+Regional+Blood+Center">Gulf Coast Regional Blood Center</a> ("GCRBC"), a non-profit community blood center serving more than 26 counties throughout the state of Texas, today announced a strategic alliance to enhance the availability of high-quality, manufacture-ready cryopreserved allogeneic leukopaks for cellular therapy research, development, and treatment.
The launch of this partnership coincides with the grand opening of Cryoport's new state-of-the-art IntegriCell&#x2122; facility located at Cryoport's integrated supply chain campus in Houston, Texas.
This collaboration brings together GCRBC's Cellular Life Solutions ("CLS") program, which specializes in allogeneic donor recruitment, management, and apheresis collection, with Cryoport's industry-leading cryopreservation and biologistics expertise, creating a comprehensive and unified service offering for the life sciences community. GCRBC's CLS program is located less than two miles from Cryoport's Houston campus, enabling efficient local transport of collected leukopaks through Cryoport's Cryoshuttle&#xAE;&nbsp;transportation service.

Biotech

General

Cryoport And Gulf Coast Regional Blood Center Announce A Strategic Alliance To Enhance The Availability Of High-Quality, Manufacture-Ready Cryopreserved Allogeneic Leukopaks For Cellular Therapy Research, Development, And Treatment.

Two ISO-Certified Industry Leaders Collaborate to Provide Fertility Clinics with Complete, Trusted&nbsp; Solutions for Secure IVF Specimen Management and Transport

TMRW Life Sciences And CryoPort Systems Form Strategic Partnership To Improve Standards For Frozen Egg, Embryo, And Sperm Offsite Storage And Biologistics

In the latest quarter, 5 analysts provided ratings for CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>), showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated CryoPort and provided 12-month price targets. The average target is $10.0, accompanied by a high estimate of $15.00 and a low estimate of $7.00. Experiencing a 38.27% decline, the current average is now lower than the previous average price target of $16.20. 
<img src="https://www.benzinga.com/files/images/story/2024/1729263648_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of CryoPort's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dan Leonard</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Dan Leonard</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$7.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Matthew Stanton</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$8.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$11.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Yuan Zhi</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$19.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CryoPort. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CryoPort compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of CryoPort's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of CryoPort's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CYRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CryoPort analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About CryoPort</h2>
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
<h3>CryoPort: A Financial Overview</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, CryoPort showcased positive performance, achieving a revenue growth rate of 1.01% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: CryoPort's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -138.88%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): CryoPort's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -19.66%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): CryoPort's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -8.91%, the company may face hurdles in achieving optimal financial returns.
Debt Management: CryoPort's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.09, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Peeling Back The Layers: Exploring CryoPort Through Analyst Insights

UBS analyst Dan Leonard maintains CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) with a Neutral and raises the price target from $7 to $9.

UBS Maintains Neutral on CryoPort, Raises Price Target to $9

The IntegriCell Platform Will Deliver High-Quality Cryopreservation Services for Cell-Based Therapies

Cryoport Launches IntegriCell Cryopreservation Solution; Open Facility At Houston Campus

CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $10.25, with a high estimate of $15.00 and a low estimate of $7.00. This current average has decreased by 44.59% from the previous average price target of $18.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1723057748_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of CryoPort by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dan Leonard</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$7.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Matthew Stanton</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$8.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$11.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Yuan Zhi</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$19.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CryoPort. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CryoPort compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of CryoPort's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of CryoPort's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CYRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CryoPort analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering CryoPort: A Closer Look</h2>
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
<h3>Understanding the Numbers: CryoPort's Finances</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Decline in Revenue: Over the 3 months period, CryoPort faced challenges, resulting in a decline of approximately -13.09% in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: CryoPort's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -38.27%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): CryoPort's ROE excels beyond industry benchmarks, reaching -4.61%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -2.2%, the company showcases effective utilization of assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.93, caution is advised due to increased financial risk.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Key Takeaways From CryoPort Analyst Ratings

UBS analyst Dan Leonard maintains CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) with a Neutral and lowers the price target from $17 to $7.

UBS Maintains Neutral on CryoPort, Lowers Price Target to $7

U.S. stock futures were higher this morning, with the Dow futures gaining around 300 points on Wednesday.
Shares of Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) dipped 15.8% to $109.68 after the company reported worse-than-expected second-quarter EPS results and issued third-quarter revenue <a href="https://www.benzinga.com/markets/equities/24/08/40213199/why-airbnb-stock-is-down-16-in-wednesday-pre-market">guidance below estimates</a>.
Airbnb's second-quarter sales of $2.748 billion exceeded the analyst consensus estimate of $2.738 billion, marking a 10.63% increase from the same period last year. However, the company's quarterly GAAP earnings of 86 cents per share fell short of the analyst consensus estimate of 92 cents, missing the mark by 6.52%.
ZoomInfo Technologies shares dipped 15.2% to $8.31 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares dipped 36.2% to $6.27 in pre-market trading after posting a loss for the second quarter.</li>
<li>Nevro Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) shares declined 31.1% to $5.99 in pre-market trading after the company reported worse-than-expected second-quarter sales results.</li>
<li>National Vision Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYE#NASDAQ">EYE</a>) dipped 24.8% to $10.50 in pre-market trading following weak quarterly sales.</li>
<li>Cryoport, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) shares slipped 23.5% to $5.95 in pre-market trading after posting weak quarterly sales.</li>
<li>The RealReal, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REAL#NASDAQ">REAL</a>) dipped 19.4% to $2.50 in pre-market trading following second-quarter results.</li>
<li>Trex Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TREX#NYSE">TREX</a>) fell 16.7% to $63.75 in pre-market trading after the company reported worse-than-expected second-quarter sales results.</li>
<li>ACADIA Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) dipped 16.7% to $15.70 following second-quarter results.</li>
<li>Progyny, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGNY#NASDAQ">PGNY</a>) fell 16.5% to $21.48 in pre-market trading after the company reported worse-than-expected second-quarter revenue results.</li>
<li>Tripadvisor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIP#NASDAQ">TRIP</a>) fell 15.4% to $13.80 in pre-market trading after the company reported worse-than-expected second-quarter sales results.</li>
<li>Lyft, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) shares declined 14.2% to $9.41 following second-quarter financial results.</li>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) dipped 8.1% to $13.60 after the company reported worse-than-expected quarterly adjusted EPS results.</li>
<li>Ashland Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASH#NYSE">ASH</a>) dipped 6.2% to $84.78 following weak quarterly sales.</li>
<li>Expedia Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) fell 3.8% to $113.05.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40194186/top-4-materials-stocks-which-could-rescue-your-portfolio-this-month">Top 4 Materials Stocks Which Could Rescue Your Portfolio This Month</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

ABNB

ACAD

EXPE

LYFT

NVRO

PGNY

REAL

RIVN

TREX

TRIP

Airbnb Reports Weak Earnings, Joins Cryoport, Tripadvisor, Lyft And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Jefferies analyst Matthew Stanton downgrades CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) from Buy to Hold and lowers the price target from $20 to $8.

Downgrades

Jefferies Downgrades CryoPort to Hold, Lowers Price Target to $8

CryoPort shares are trading lower after the company reported mixed Q2 financial results and issued FY24 revenue guidance below estimates. Also, Needham maintained a Buy rating on the stock and lowered its price target from $18 to $11.

Shares of Fortinet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter financial results and<a href="https://www.benzinga.com/news/earnings/24/08/40203474/fortinet-q2-earnings-revenue-beat-eps-beat-strong-guidance-and-more"> issued guidance above estimates.</a>
Fortinet's second-quarter revenue increased 11% year-over-year to $1.43 billion, beating consensus estimates of $1.403 billion. The cybersecurity company reported second-quarter adjusted earnings of 57 cents per share, beating analyst estimates of 41 cents per share.
Fortinet shares jumped 17% to $65.29 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Richtech Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RR#NASDAQ">RR</a>) rose 68.1% to $0.6220 in today's pre-market trading after dipping around 74% on Tuesday.</li>
<li>Lumen Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) gained 43% to $7.15 in pre-market trading after the company reported better-than-expected second-quarter revenue results.</li>
<li>Zhongchao Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCMD#NASDAQ">ZCMD</a>) gained 34.2% to $1.65 in pre-market trading.</li>
<li>Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) jumped 24% to $29.60 in pre-market trading after the company reported better-than-expected second-quarter financial results and issued third-quarter revenue guidance above estimates.</li>
<li>Latham Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) shares gained 20.6% to $3.75 in pre-market trading after the company reported better-than-expected second-quarter financial results and raised its FY24 revenue guidance above estimates. Additionally, the company announced an acquisition of Coverstar Central.</li>
<li>Mynd.ai, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYND#NYSE">MYND</a>) shares rose 15.9% to $2.55 in pre-market trading after falling around 7% on Tuesday.</li>
<li>Beyond Air, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) shares rose 14.3% to $0.5770 in pre-market trading after the company reported better-than-expected quarterly EPS results.</li>
<li>Snow Lake Resources Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITM#NASDAQ">LITM</a>) gained 12.8% to $0.5756 in pre-market trading after jumping around 13% on Tuesday.</li>
<li>Corvus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) shares gained 10% to $3.30 in pre-market trading after the company reported a narrower-than-expected quarterly loss.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Scorpius Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#NYSE">SCPX</a>) shares dipped 77% to $1.30 in pre-market trading after gaining 19% on Tuesday. Scorpius announced that it has surpassed $100 million in near-term business development opportunities across government and commercial sectors.</li>
<li>Talis Biomedical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLIS#NASDAQ">TLIS</a>) shares declined 52.7% to $4.25 in pre-market trading after the company initiated a board restructuring.</li>
<li>Porch Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCH#NASDAQ">PRCH</a>) declined 38.2% to $1.07 in pre-market trading after reporting weak quarterly results.</li>
<li>Stem, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) shares declined 37.1% to $0.6274 in pre-market trading after the company reported mixed second-quarter financial results.</li>
<li>Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares fell 36.2% to $6.27 in pre-market trading after posting a loss for the second quarter.</li>
<li>DZS Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DZSI#NASDAQ">DZSI</a>) fell 36.2% to $0.66 pre-market trading after the company announced it received a delisting notice from the Nasdaq.</li>
<li>VBI Vaccines Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBIV#NASDAQ">VBIV</a>) fell 32.2% to $0.09 in today's pre-market trading after jumping 111% on Tuesday.</li>
<li>Nevro Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) shares fell 31.1% to $5.99 in pre-market trading after the company reported worse-than-expected second-quarter sales results.</li>
<li>Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) fell 24.5% to $2.90 in pre-market trading after declining around 11% on Tuesday.</li>
<li>Cryoport, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) shares fell 23.5% to $5.95 in pre-market trading after posting weak quarterly sales.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40194186/top-4-materials-stocks-which-could-rescue-your-portfolio-this-month">Top 4 Materials Stocks Which Could Rescue Your Portfolio This Month</a></li>
</ul>

CRVS

DZSI

FTNT

LITM

LUMN

MYND

PRCH

SCPX

STEM

SWIM

TLIS

UPST

VBIV

XAIR

ZCMD

Why Fortinet Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

Needham analyst David Saxon maintains CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) with a Buy and lowers the price target from $18 to $11.

Needham Maintains Buy on CryoPort, Lowers Price Target to $11

Cryport Sees FY24 Revenue $225M-$235M Vs $240.513M Est.

CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.39) by 25.64 percent. The company reported quarterly sales of $57.597 million which missed the analyst consensus estimate of $57.684 million by 0.15 percent. This is a 1.01 percent increase over sales of $57.021 million the same period last year.

CryoPort Q2 2024 Adj. EPS $(0.29) Beats $(0.39) Estimate, Sales $57.597M Miss $57.684M Estimate

WIIM

CryoPort shares are trading lower. The company reported Q2 financial results.

<ul>
<li>$200 million repurchase program authorized to repurchase common stock and/or convertible notes &nbsp;</li>
<li>Repurchasing approximately $160 million of 0.75% Senior Notes due in 2026 at an 11.5% discount to par value &nbsp;</li>
<li>Principal balance reduced to approximately $186.2 million</li>
</ul>
NASHVILLE, Tenn., Aug. 6, 2024 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4227527-1&amp;h=180862197&amp;u=https%3A%2F%2Fcryoportinc.com%2F&amp;a=Cryoport%2C+Inc.">Cryoport, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences, today announced that the Company's Board of Directors had authorized a repurchase program to purchase up to $200 million of the Company's common stock and/or convertible senior notes (the "2024 Repurchase Program").&nbsp; The 2024 Repurchase Program became effective on August 1, 2024 and remains in effect through December 31, 2027.&nbsp;
The Company also announced that it has entered into agreements with certain holders of its 0.75% Convertible Senior Notes due in 2026 (the "2026 Notes") to repurchase $160 million in aggregate principal amount of the 2026 Notes (the "Transactions") for an aggregate repurchase price of $141.6&nbsp;million, plus accrued and unpaid interest. &nbsp;The Transactions were made under the 2024 Repurchase Program.

Buybacks

CryoPort Announces $200M Repurchase Program And The Repurchase Of $160M Of Convertible Senior Notes

CryoPort shares are trading higher after B. Riley Securities upgraded the stock from Neutral to Buy.

CryoPort Q3 2024 Earnings Preview

16:54 EST Cryoport (CYRX) still sees 2024 revenue $225M-$235M, consensus $229.73M Published first on TheFly – the ultimate source for real-time, ma...

Cryoport still sees 2024 revenue $225M-$235M, consensus $229.73M

CryoPort GAAP EPS of -$0.02 beats by $0.29, revenue of $56.66M misses by $1.47M

CryoPort Inc ( ($CYRX) ) has released its Q3 earnings. Here is a breakdown of the information CryoPort Inc presented to its investors. Cryoport, In...

Cryoport Reports Growth in Life Sciences Services

Needham analyst David Saxon reiterated a Buy rating on CryoPort (CYRX – Research Report) today and set a price target of $11.00. David Saxon has gi...

CryoPort: Buy Rating Affirmed Amid Promising Profitability Outlook and Attractive Valuation

Cryoport, Inc. 2024 Q3 - Results - Earnings Call Presentation

Cryoport, Inc. (CYRX) Q3 2024 Earnings Call Transcript

CryoPort (CYRX – Research Report), the Industrials sector company, was revisited by a Wall Street analyst on November 7. Analyst Puneet Souda from ...

CryoPort's Hold Rating: Navigating Challenges Amidst Market Uncertainties

BTIG analyst David Larsen maintained a Buy rating on CryoPort (CYRX – Research Report) today and set a price target of $13.00. The company's shares...

CryoPort (CYRX) Receives a Buy from BTIG

Morgan Stanley analyst Tejas Savant has maintained their neutral stance on CYRX stock, giving a Hold rating on November 8. Tejas Savant's rating is...

CryoPort 3Q24 Analysis: Hold Rating Amid Market Challenges and Growth Potential

Small Cap

Press Releases

Cryoport Announces $200 Million Repurchase Program and the Repurchase of $160 Million of Convertible Senior Notes

Cryoport Reports Second Quarter 2024 Financial Results

SK pharmteco and Cryoport Partner for Cell and Gene Therapy Logistics and BioServices

Cryoport Launches its IntegriCell™ Cryopreservation Solution with Opening of New Facility at its Houston Campus

VGXI Selects Cryoport for Biostorage, Bioservices and Supply Chain Solutions to Advance Next-Generation Therapies

Contracts

TMRW Life Sciences and Cryoport Systems Form Strategic Partnership to Elevate Standards for Frozen Egg, Embryo, and Sperm Offsite Storage and Biologistics

Comments

CryoPort

Vendite allo scoperto

CryoPort (NASDAQ:CYRX) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO